Scientific Programme

Tuesday 14th November 2023

Listed times are in Central European Time (CET)

11:30  REGISTRATION & WELCOME LUNCH (LUNCH FROM 12:00)
13:00  WELCOME TO DAY ONE

SESSION 1 - TECHNOLOGIES AND GENOMICS
Chair: Sophie Postel-Vinay

13:10  OPENING KEYNOTE LECTURE
Scott Lowe
Memorial Sloan Kettering Cancer Centre, New York, USA
"Understanding and exploiting tumor suppressive programs"
Q&A: 13:45-13:55

13:55  Céline Vallot
Institut Curie, Paris, France
"Mechanisms of cell plasticity in breast cancers"
Q&A: 14:15-14:25

14:25  Mirja Rotinen
Public University of Navarre, Pamplona, Spain
Proffered Paper 1: "ONECUT2 is a targetable lineage plasticity modulator of breast cancer that suppresses the estrogen axis"

14:40  EXHIBITOR INTRODUCTIONS

14:50  COFFEE BREAK & EXHIBITION

15:20  Jean Soulier
Hôpital Saint-Louis, INSERM, Paris, France
"Secondary leukemia to stressed hematopoiesis"
Q&A: 15:40-15:50

15:50  Renata Basto
Institut Curie, Paris, France
"Centrosome amplification induces apoptotic priming and favors the response to chemotherapy in epithelial ovarian cancer beyond multipolar divisions"
Q&A: 16:10-16:20

16:20  POSTER SPOTLIGHTS

16:30  MEET THE EXPERT SESSION
Yves Pommier, National Cancer Institute, Center for Cancer Research, Bethesda, USA; Céline Vallot, Institut Curie, Paris, France

17:00  WELCOME RECEPTION
### Wednesday 15th November 2023

**Listed times are in Central European Time (CET)**

**08:30**  EARLY POSTER VIEWING

**SESSION 2: LEUKEMIA THERAPY**

**Chair:** Patrick Mehlen

**09:00**  Andreas Trumpp
German Cancer Research Centre (DKFZ), Heidelberg, Germany

“MAC-scoring in leukemic stem cells predicts response to Venetoclax in AML patients”

Q&A: 09:20-09:30

**09:30**  Irina Korovina
HZDR – Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany

Proffered Paper 2: “Integrin α2-deficiency reduces treatment resistance in glioblastoma by modulating ATF1 activity”

**09:45**  Hugues de Thé
College de France, Paris, France

“From nuclear architecture to leukemia cure: emerging roles of PML”

Q&A: 10:05-10:15

**10:15**  Yves Pommier
National Cancer Institute, Center for Cancer Research, Bethesda, MA, USA

“Genomics and Schlafen 11 (SLFN11) as predictors in oncology clinical trials”

Q&A: 10:35-10:45

**11:15**  Julien Ablain
CRCL, Lyon, France

“Investigating the mechanisms of melanoma development and therapy response using zebrafish”

Q&A: 11:35-11:45

**11:45**  Laura Broutier
CRCL, Lyon, France

Proffered Paper 3: “Modelling the next-generation of fusion-negative rhabdomyosarcoma 3D-organoids to predict effective drug combinations: a proof-of-concept on cell death inducers”

**12:00**  POSTER SPOTLIGHTS

**12:10**  LUNCH & EXHIBITION

**13:10**  POSTER DISCUSSION SESSION 2

**SESSION 3: NOVEL APPROACHES TO DRUG SENSITIVITY**

**Chair:** Hugues de The

**14:40**  Sophie Postel-Vinay
IGR, Paris, France

“Harnessing genetic vulnerabilities in immuno-oncology: novel therapeutic opportunities”
Q&A: 15:00-15:10

15:10 Mattia Marinucci  
University of Basel, Basel, Switzerland  
Proffered Paper 4: "(Phospho)Proteomic analysis reveals vulnerabilities in metastatic colorectal cancer"

15:25 Hyunbin Huh  
Yonsei, Seoul, South Korea  
Proffered Paper 5: "Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination"

15:40 Patrick Mehlen  
Lyon Cancer Research Center (CRCL), Paris, France  
"Targeting netrin-1 in cancer: from mechanisms of cell death to patients"  
Q&A: 16:00-16:10

16:10 COFFEE BREAK & EXHIBITION

16:40 Fanny Jaulin  
Gustave Roussy, Villejuif, France  
"Organoids as tools for functional precision medicine in advanced pancreatic cancer"  
Q&A: 17:00-17:10

17:10 THE EMBO KEYNOTE LECTURE  
Cedric Blanpain  
Laboratory of Stem Cells and Cancer, ULB, Brussels, Belgium  
"Targeting EMT mediated resistance to therapy"  
Q&A: 17:30-17:40

17:40 PANEL DISCUSSION

19:30 CONFERENCE DINNER  
The 3-course dinner will be at the Hotel Crowne Plaza Lyon’s restaurant, Bistrot Rive Gauche. Optional ticketed event.

Thursday 16th November 2023

LISTED TIMES ARE IN CENTRAL EUROPEAN TIME (CET)

08:30 EARLY POSTER VIEWING  
SESSION 4: METABOLISM AND SENESCENCE  
Chair: Sophie Postel-Vinay

09:00 Filipe Cabriero  
MRC London Institute of Medical Sciences, London, UK  
"Microbially derived adjuvants for cancer chemotherapy"  
Q&A: 09:20-09:30

09:30 Jean-Emmanuel Sarry  
Centre de Recherches en Cancérologie de Toulouse (Oncopole), Toulouse, France  
"Metabolic bases of drug resistance in acute myeloid leukemia"  
Q&A: 09:50-10:00
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Proffered Paper 6: Targeting exostosin glycosyltransferase 2 (EXT2) modulates glioblastoma cell metabolism, sensitizing to X-ray irradiation via ferroptosis</td>
<td>Rocio Matesanz Sanchez, OncoRay – National Center for Radiation Research in Oncology, Dresden, Germany</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>COFFEE BREAK &amp; EXHIBITION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Geraldine Gentric</td>
<td>Institut Curie, Paris, France</td>
<td>Role of stromal heterogeneity in resistance to treatments</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Q&amp;A:</strong> 11:05-11:15</td>
</tr>
<tr>
<td>11:15</td>
<td>Closing Keynote - Clemens Schmitt</td>
<td>Max Delbruck Center, Berlin, Germany</td>
<td>Apoptosis-competent anticancer treatment failure</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Q&amp;A:</strong> 11:50-12:00</td>
</tr>
<tr>
<td>12:00</td>
<td>SUMMARY &amp; CLOSE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>